Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 21252264.
- Also identified by DOI 10.1093/jnci/djq531.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This 12th biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials in the field of hemato-oncology, covering the publication period from September 1, 2009, through June 30, 2010. Implication for clinical practice and methodological aspects are the main principles used to select trials for this report. Studies on tyrosine kinase inhibitors for patients with chronic myeloid leukemia were identified through electronic search of MEDLINE with a broad search filter that covered all topics in hemato-oncology combined with a highly sensitive search filter for randomized studies as described in the Cochrane Handbook for Systematic Reviews of Interventions.
Medical subject headings
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Protein Kinase Inhibitors
- Protein-Tyrosine Kinases